A new generative AI model trained on UK Biobank data can simultaneously forecast the risks and timing of developing over 1,000 different diseases a decade into the future. The developers applied similar algorithmic concepts to those used to develop large language models like ChatGPT and Gemini to build the model, using medical records from 402,799 participants in UK Biobank. Read More
Nipah virus (NiV) and Hendra virus (HeV) are highly pathogenic henipaviruses that cause severe respiratory and neurological disease in humans, often with high fatality rates. To date, NiV has caused 749 cases across nine countries with 43%-100% fatality rates, while HeV infections are fewer but similarly lethal (57%). Read More
Immuto Scientific Inc. has closed an $8 million seed 2 financing round and entered into a drug discovery collaboration with Daiichi Sankyo Co. Ltd. Immuto applies its target discovery platform and structural epitope‑mapping engine to identify disease‑specific surface protein conformations. Read More
Mabwell (Shanghai) Bioscience Co. Ltd. and Aditum Bio Management Company LLC have announced the launch of Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement to develop 2MW7141. Read More
Osteosarcoma, the most common bone cancer in children and young adults, has poor outcomes after relapse with only ~18% 5-year survival, underscoring the urgent need for new therapies. Researchers from New York Medical College and colleagues have now demonstrated a new strategy to improve the efficacy of natural killer (NK) cell-based immunotherapy for osteosarcoma. Read More
Glioblastoma multiforme (GBM) is the most aggressive and common type of brain cancer in adults, with a dismal prognosis despite current treatments. Previous work found that neurodevelopmental pathways drive glioma tumor initiation, maintenance and progression through fetal oncogenes, which are active in development and cancer but largely absent in adult tissues, offering precise therapeutic targets with minimal off-target effects. Read More
N6-methyladenosine (m6A) modification, mainly controlled by the m6A methyltransferase METTL3, is crucial for RNA regulation and the development of leukemia. However, how METTL3 stability and function are regulated after translation is not fully understood. Since O-GlcNAcylation commonly modifies nuclear and cytosolic proteins, researchers have hypothesized that METTL3 may be O-GlcNAcylated, affecting its stability and oncogenic activity in myeloid malignancies. Read More
Almirall SA has disclosed tyrosine-protein kinase ITK/TSK (EMT) inhibitors reported to be useful for the treatment of atopic dermatitis, psoriasis, alopecia areata, vitiligo, T-cell lymphoma, asthma, inflammatory bowel disease and multiple sclerosis, among others. Read More
Nanjing Zaiming Pharmaceutical Co. Ltd. has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer. Read More
Shanghai Yingli Pharmaceutical Co. Ltd. has divulged phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer. Read More
Chengdu Kanghong Pharmaceutical Co. Ltd. has identified DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer. Read More
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has described isocitrate dehydrogenase (NADP) cytoplasmic (IDH1; PICD; IDP) (mutant) inhibitors reported to be useful for the treatment of glioma. Read More
Additional early-stage research and drug discovery news in brief, from: Biomea Fusion, Cidara Therapeutics, Kura Oncology, Mira Pharmaceuticals. Read More
